Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET
Company Participants
Chris Calabrese - MD, LifeSci Advisors
Ted White - President & CEO
Joe Bonaccorso - CCO
Terry Kohler - CFO
Gary Goldenberg - CMO
Chris Hayes - Chief Legal Officer
Conference Call Participants
Stacy Ku - TD Cowen
Anish Nikhanj - RBC Capital Markets
Glen Santangelo - Jefferies
Oren Livnat - H.C. Wainwright
Serge Belanger - Needham and Company
Kemp Dolliver - Brookline Capital Markets
Operator
Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Chris Calabrese from LifeSci Advisors. Please go ahead.
Chris Calabrese
Thank you, Operator. Hello, everyone, and welcome to Verrica Pharmaceuticals first quarter 2024 corporate update and earnings conference call.
With me on the line this morning are Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals; Joe Bonaccorso, Chief Commercial Officer; Terry Kohler, Chief Financial Officer; Dr. Gary Goldenberg, Verrica's Chief Medical Officer; and Chris Hayes, Verrica's Chief Legal Officer.
As a reminder, during today's call, management will make forward-looking statements. These statements may include expectations related to the launch and commercialization of YCANTH for the treatment of molluscum contagiosum in the United States, regulatory developments, the developments of Verrica's product candidates, our expected cash runway, our potential agreements with Torii and Dormer Labs, as well as overall business strategy and planned operations.
These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. And based on those risks and uncertainties, Verrica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements.
Please see Verrica's SEC filings for important Risk Factors. Verrica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations.
In addition, during today's call, we will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in addition to and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures versus their closest GAAP equivalent.